<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03748134</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI308A301</org_study_id>
    <nct_id>NCT03748134</nct_id>
  </id_info>
  <brief_title>Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma</brief_title>
  <acronym>ORIENT-15</acronym>
  <official_title>A Multicenter, Double-Blind, Randomized Phase 3 Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination With Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind multi-center, phase III study comparing the efficacy and
      safety of sintilimab or placebo in combination with chemotherapy as first-line treatment in
      subjects with unresectable, locally advanced recurrent or metastatic esophageal squamous cell
      carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 13, 2018</start_date>
  <completion_date type="Anticipated">July 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 14, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>OS in overall population</measure>
    <time_frame>From date of randomization until the date of death from any cause, assessed up to 40 months.</time_frame>
    <description>To compare the overall survival of sintilimab vs. placebo, in combination with chemotherapy, for first-line treatment in subjects with unresectable, locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OS in PD-L1 positive population</measure>
    <time_frame>From date of randomization until the date of death from any cause, assessed up to 40 months.</time_frame>
    <description>To compare the OS of sintilimab vs. placebo, in combination with chemotherapy, for first-line treatment in subjects with PD-L1 positive, unresectable, locally advanced, recurrent or metastatic ESCC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR in overall population</measure>
    <time_frame>From date of randomization up to 28 months.</time_frame>
    <description>To compare the objective response rate between the two treatment arms in ITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS in overall populationsubjects in ITT population</measure>
    <time_frame>From date of randomization up to 28 months</time_frame>
    <description>To compare the progression-free survival between the two treatment arms in ITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR in overall population</measure>
    <time_frame>From date of randomization up to 28 months</time_frame>
    <description>To compare the disease control rate between the two treatment arms in ITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DoR in overall population</measure>
    <time_frame>From date of randomization up to 28 months</time_frame>
    <description>To compare the duration of response between the two treatment arms in ITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR - PD-L1 positive</measure>
    <time_frame>From date of randomization up to 28 months</time_frame>
    <description>To compare the objective response rate between the two treatment arms in PD-L1 positive subjects in ITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR - PD-L1 positive</measure>
    <time_frame>From date of randomization up to 28 months</time_frame>
    <description>To compare the disease control rate between the two treatment arms in PD-L1 positive subjects in ITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DoR - PD-L1 positive</measure>
    <time_frame>From date of randomization up to 28 months</time_frame>
    <description>To compare the duration of response between the two treatment arms in PD-L1 positive subjects in ITT population</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">676</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Sintilimab + chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sintilimab in combination with investigator's choice of chemotherapy
TP regimen: Cisplatin + paclitaxel
or
CP regimen: Cisplatin + fluorourcil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo in combination with investigator's choice of chemotherapy
TP regimen: Cisplatin + paclitaxel
or
CP regimen: Cisplatin + fluorourcil</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sintilimab</intervention_name>
    <description>For weight &lt;60kg, 3mg/kg IV Q3W day 1, and for weight≥60kg, 200mg IV Q3W day 1</description>
    <arm_group_label>Sintilimab + chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>For weight &lt;60kg, 3mg/kg IV Q3W day 1, and for weight≥60kg, 200mg IV Q3W day 1</description>
    <arm_group_label>Placebo + chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>75mg/m^2 IV Q3W day 1</description>
    <arm_group_label>Placebo + chemotherapy</arm_group_label>
    <arm_group_label>Sintilimab + chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>87.5 mg/m^2 IV Q3W day 1, day 8 for first cycle and 175mg/m^2 IV Q3W day 1 after first cycle</description>
    <arm_group_label>Placebo + chemotherapy</arm_group_label>
    <arm_group_label>Sintilimab + chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <description>800 mg/m^2 IV continuous infusion over 24 hours daily on Days 1-5 Q3W</description>
    <arm_group_label>Placebo + chemotherapy</arm_group_label>
    <arm_group_label>Sintilimab + chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Histopathologically confirmed unresectable, locally advanced, recurrent or metastatic
             ESCC (excluding mixed adenosquamous carcinoma and other histological subtypes)

          -  ECOG PS of 0 or 1

          -  Subject must be unsuitable for definitive treatment, such as definitive
             chemoradiotherapy and/or surgery. For subjects who have received (neo)adjuvant or
             definitive chemotherapy/radiochemotherapy, time from the completion of last treatment
             to disease recurrence must be &gt; 6 months Could provide archival or fresh tissues for
             PD-L1 expression analysis with obtainable results#

          -  Have at least one measurable lesion as per RECIST v1.1

        Key exclusion Criteria:

          -  ESCC with endoscopy-confirmed near-complete obstruction requiring interventional
             therapy

          -  Post stent implantation in the esophagus or trachea with risk of perforation

          -  Received systemic treatment for advanced or metastatic ESCC.

          -  Received a Cumulative dose of cisplatin &gt; 300 mg/m2 within 12 months to randomization.

          -  High risk of hemorrhage or perforations due to tumor invasion in adjacent organs
             (aorta or trachea), or have fistula formation.

          -  Hepatic metastasis &gt; 50% of the total liver volume.

          -  Received palliative therapy for a local lesion within 2 weeks prior to the first dose.

          -  Received systemic treatment with Chinese traditional medicines with anti-cancer
             indications or immunomodulators (including thymosins, interferons, and interleukins)
             within 2 weeks prior to the first dose of study treatment.

          -  Received systemic immunosuppressants within 2 weeks prior to randomization, excluding
             local use of glucocorticoids administered by nasal, inhaled, or other routes, and
             systemic glucocorticoids at physiological doses (no more than 10 mg/day of prednisone
             or equivalents), or glucocorticoids to prevent allergies to contrast media.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Agnes Sun</last_name>
    <phone>+86 21 31820291</phone>
    <email>xiaolei.sun@innoventbio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peter Pan</last_name>
    <phone>+86 21 31655781</phone>
    <email>xinchun.pan@innoventbio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. Joseph Heritage Healthcare - Virginia K. Crosson Cancer Center</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>714-446-5900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UC Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>949-824-5011</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers, LLP</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>719-577-2555</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>IACT Health - John B. Amos Cancer center</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>706-320-8700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oklahoma University Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>405-271-1112</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>512-427-9400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists, P.C.</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98684</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>855-404-6727</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Queen Elizabeth Hospital</name>
      <address>
        <city>Woodville South</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+65-8-8222 6000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiahui Liu</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>China</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 12, 2018</study_first_submitted>
  <study_first_submitted_qc>November 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2018</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ESCC</keyword>
  <keyword>Esophageal Cancer</keyword>
  <keyword>Esophageal Neoplasms</keyword>
  <keyword>Esophageal Neoplasms Malignant</keyword>
  <keyword>Esophageal Squamous Cell Carcinoma</keyword>
  <keyword>Neoplasms, Squamous Cell</keyword>
  <keyword>Esophageal Diseases</keyword>
  <keyword>Carcinoma, Squamous Cell</keyword>
  <keyword>Gastrointestinal Diseases</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Fluorouracil</keyword>
  <keyword>Antineoplastic Agents</keyword>
  <keyword>Anti-PD-1</keyword>
  <keyword>Sintilimab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

